within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AA07_Acenocoumarol;

model Acenocoumarol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 5.833333333333334e-07,
    adminDuration = 600,
    adminMass = 8 / 1000000,
    adminCount = 1,
    Vd = 0.000125,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.013333333333333334,
    Tlag = 600,
    Vdp = 0.00021799999999999999,
    k12 = 8.861111111111112e-07,
    k21 = 8.861111111111112e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Acenocoumarol</td></tr><tr><td>ATC code:</td><td>B01AA07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>8</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.125</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Acenocoumarol is a vitamin K antagonist oral anticoagulant, structurally related to warfarin, used for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and for stroke prevention in atrial fibrillation. It is approved and used in several countries, though not in the United States.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Thijssen, HH, et al., &amp; de Vries-Hanje, JC (2001). Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. <i>Clinical pharmacology and therapeutics</i> 70(3) 292–298. DOI:<a href=\"https://doi.org/10.1067/mcp.2001.117936\">10.1067/mcp.2001.117936</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11557918/\">https://pubmed.ncbi.nlm.nih.gov/11557918</a></p></li><li><p>Stehle, S, et al., &amp; Fuhr, U (2008). Pharmacogenetics of oral anticoagulants: a basis for dose individualization. <i>Clinical pharmacokinetics</i> 47(9) 565–594. DOI:<a href=\"https://doi.org/10.2165/00003088-200847090-00002\">10.2165/00003088-200847090-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18698879/\">https://pubmed.ncbi.nlm.nih.gov/18698879</a></p></li><li><p>Villapalos-García, G, et al., &amp; Abad-Santos, F (2023). NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 165 115058–None. DOI:<a href=\"https://doi.org/10.1016/j.biopha.2023.115058\">10.1016/j.biopha.2023.115058</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37385211/\">https://pubmed.ncbi.nlm.nih.gov/37385211</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B01AA07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Acenocoumarol;
